Agios Pharmaceuticals (AGIO) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zenas BioPharma (ZBIO) has outperformed Agios Pharmaceuticals (AGIO) over the past year, gaining 1.3% versus a loss of 25.1%. Agios Pharmaceuticals is the larger company by market cap ($1.91 billion vs $1.71 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | ZBIO |
|---|---|---|
| Share price | $31.92 | $26.24 |
| Market cap | $1.91B | $1.71B |
| 1-day change | +0.41% | -6.88% |
| YTD return | +17.27% | -27.73% |
| 1-year return | -25.07% | +1.31% |
| 5-year return | -31.31% | — |
| EPS (TTM) | $-7.01 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.00 | $44.60 |
| 52-week low | $22.24 | $13.50 |
| Distance from 52-week high | -30.61% | -41.17% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +44.11% | +82.47% |
| Average volume | 1.08M | 735.12K |
| Shares outstanding | 59.70M | 65.18M |
| Employees | 539 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZBIO has outperformed AGIO by 26.4 percentage points over the past year.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
AGIO vs ZBIO FAQ
Which is bigger, Agios Pharmaceuticals or Zenas BioPharma?
Agios Pharmaceuticals (AGIO) is larger, with a market capitalization of $1.91B compared with $1.71B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, AGIO or ZBIO?
ZBIO returned +1.31% over the past 12 months, compared with -25.07% for AGIO (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.